Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival

Abstract

Background The expression signature of deregulated long non-coding RNAs (lncRNAs) and related genetic variants is implicated in every stage of tumorigenesis, progression, and recurrence. This study aimed to explore the association of lncRNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) gene expression and the rs2383207A>G intronic variant with breast cancer (BC) risk and prognosis and to verify the molecular role and networks of this lncRNA in BC by bioinformatics gene analysis. Methods Serum CDKN2B-AS1 relative expression and rs2383207 genotypes were determined in 214 unrelated women (104 primary BC and 110 controls) using real-time PCR. Sixteen BC studies from The Cancer Genome Atlas (TCGA) including 8925 patients were also retrieved for validation of results. Results CDKN2B-AS1 serum levels were upregulated in the BC patients relative to controls. A/A genotype carriers were three times more likely to develop BC under homozygous (OR = 3.27, 95% CI 1.20–8.88, P = 0.044) and recessive (OR = 3.17, 95% CI 1.20–8.34, P = 0.013) models. G/G homozygous patients had a higher expression level [median and quartile values were 3.14 (1.52–4.25)] than A/G [1.42 (0.93–2.35)] and A/A [1.62 (1.33–2.51)] cohorts (P = 0.006). The Kaplan–Meier curve also revealed a higher mean survival duration of G/G cohorts (20.6 months) compared to their counterparts (A/A: 15.8 and A/G: 17.2 months) (P < 0.001). Consistently, BC data sets revealed better survival in cohorts with high expression levels (P = 0.003). Principal component analysis (PCA) showed a deviation of patients who had shorter survival towards A/A and A/G genotypes, multiple lesions, advanced stage, lymphovascular invasion, and HER2+ receptor staining. Ingenuity Pathway Analysis (IPA) showed key genes highly enriched in BC with CDKN2B-AS1. Conclusions The findings support the putative role of CDKN2B-AS1 as an epigenetic marker in BC and open a new avenue for its potential use as a therapeutic molecular target in this type of cancer.

Differential Effect of Three Macrolide Antibiotics on Cardiac Pathology and Electrophysiology in a Myocardial Infarction Rat Model: Influence on Sodium Nav1.5 Channel Expression

“…The appropriate negative controls that do not include either the template or reverse transcriptase enzyme were run with each plate. The PCR was performed on StepOne™ Real-Time PCR System (Applied Biosystems), and the PCR program was done as reported previously [ 43 ]. The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines were followed during the PCR work, including running the appropriate negative controls with each PCR run, the blind evaluation to the study sub-groups status, and application of three technical replicates for each sample with the calculation of the mean values [ 44 ].…”

METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner

“…However, the number of human mRNAs is only about 21,000. Many lncRNAs were revealed to be dysregulated in various diseases, including HCC [ 30 – 34 ]. Moreover, many lncRNAs show important roles in various pathophysiological processes [ 35 – 42 ].…”

Analysis of anti‐apoptotic PVT1 oncogene and apoptosis‐related proteins (p53, Bcl2, PD‐1, and PD‐L1) expression in thyroid carcinoma

“…As previously described, complementary DNA (cDNA) was prepared using High‐capacity RNA‐to‐cDNA Synthesis Kit (Cat. #4390779) 30 . Real‐time quantitative polymerase chain reaction (PCR) was followed using Universal Master Mix (Cat.…”

“…#4390779). 30 Real‐time quantitative polymerase chain reaction (PCR) was followed using Universal Master Mix (Cat. #4440042) and TaqMan assay for PVT1 (Assay ID: Hs00413039_m1, Applied Biosystems, Thermo Fisher Scientific Inc.).…”